Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Phase 1 Terminated
9 enrolled
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Phase 2 Completed
98 enrolled 12 charts
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Phase 2 Withdrawn
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Phase 2 Recruiting
260 enrolled
GemTax
Phase 1/2 Completed
37 enrolled 17 charts
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Phase 2 Withdrawn
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Phase 2 Withdrawn
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
90 enrolled 12 charts
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Phase 1 Completed
47 enrolled
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Phase 1/2 Terminated
81 enrolled
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Phase 1/2 Terminated
5 enrolled 6 charts
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
Phase 2 Completed
90 enrolled
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
Phase 1/2 Completed
6 enrolled
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Phase 2 Completed
47 enrolled 7 charts
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
Phase 2 Completed
84 enrolled 7 charts
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
Phase 1 Completed
38 enrolled
STS
Phase 2 Completed
58 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Phase 2 Completed
82 enrolled
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Phase 1 Terminated
38 enrolled
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Phase 2 Completed
54 enrolled 8 charts
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Phase 2 Unknown
30 enrolled
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Phase 3 Completed
120 enrolled